Analyst Price Target is $121.80
▲ +8.53% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Hill-Rom in the last 3 months. The average price target is $121.80, with a high forecast of $130.00 and a low forecast of $115.00. The average price target represents a 8.53% upside from the last price of $112.23.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Hill-Rom. This Buy consensus rating has held steady for over two years.
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, patient mobility solutions, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising non-invasive devices that provide respiratory support and assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include tables, lights, and pendants; and positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. It sells and rents products to acute and extended care facilities through direct sales force and distributors; sells and rents products directly to patients in the home; and sells products to primary care facilities through distributors. Hill-Rom Holdings, Inc. was founded in 1915 and is headquartered in Chicago, Illinois.